THN 201
Asset
Acetylcholinesterase inhibitor combined with a connexin modulator to enhance cognitive function.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- ACHE
- 2
- Indications
- 153
- Trials
- 1
- Developer
Indications
2Alzheimer's disease
Phase 1, Completed, NCT03698695, clinicaltrials.gov, 7 Oct 2026
Cognitive impairment
Phase 1, Completed, NCT03698695, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials153
- Evidence for its targets3
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.